XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes true human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas. Show more
Location: 5217 Winnebago Lane, 8201 E Riverside Dr Ste 100, Austin, TX, 78744, United States | Website: https://www.xbiotech.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
86.28M
52 Wk Range
$2.50 - $8.32
Previous Close
$2.96
Open
$2.95
Volume
57,784
Day Range
$2.83 - $2.98
Enterprise Value
-65.35M
Cash
155.9M
Avg Qtr Burn
-7.62M
Insider Ownership
35.07%
Institutional Own.
14.92%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Hutrukin Details Brain disease, Ischemic stroke | Phase 2 Update | |
Natrunix + Methotrexate (MTX) Details Rheumatoid arthritis, Autoimmune disease | Phase 2 Update | |
Natrunix w/ ON+5FU+LV Details Cancer, Pancreatic cancer | Phase 1/2 Update | |
Natrunix + trifluridine/tipiracil Details Cancer, Colorectal cancer | Phase 1 Update | |
514G3 Details Bacterial infection, Methicillin-resistant staphylococcus aureus | Failed Discontinued | |
Bermekimab Details Skin disease/disorder | Failed Discontinued | |
Bermekimab Details Skin disease/disorder, Hidradenitis suppurativa | Failed Discontinued |